

# Zinc

A Review of Pertinent Drug Information for SARS-CoV-2

**Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDP**

**Clinical Pharmacy Specialist, Beth Israel Deaconess Medical Center**

**[mmahoney@bidmc.harvard.edu](mailto:mmahoney@bidmc.harvard.edu)**

 **@mmPharmD**

*Data as of Feb 20, 2021*



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS




# Zinc

# Chemistry & Metabolism

- Trace element
  - Cellular metabolism:
    - Required for catalytic activity of ~100 enzymes
    - Immune function
    - Protein synthesis
    - Wound healing
    - DNA synthesis
    - Cell division

<b>1</b>	<b>H</b>	Hydrogen
<b>3</b>	<b>Li</b>	Lithium
<b>11</b>	<b>Na</b>	Sodium
<b>19</b>	<b>K</b>	Potassium
<b>37</b>	<b>Rb</b>	Rubidium
<b>55</b>	<b>Cs</b>	Cesium
<b>87</b>	<b>Fr</b>	Francium
<b>4</b>	<b>Be</b>	Beryllium
<b>12</b>	<b>Mg</b>	Magnesium
<b>20</b>	<b>Ca</b>	Calcium
<b>38</b>	<b>Sr</b>	Strontrium
<b>56</b>	<b>Ba</b>	Barium
<b>88</b>	<b>Ra</b>	Radium



National Institutes of Health. Zinc Fact Sheet. <https://ods.od.nih.gov/factsheets/Zinc-HealthProfessionals/>

# Zinc

# Doses & Toxicity

## Recommended Daily Intake:

Age	Male	Female
0-6 months	2 mg	2 mg
7-12 months	3 mg	3 mg
1-3 years	3 mg	3 mg
4-8 years	5 mg	5 mg
9-13 years	8 mg	8 mg
14-18 years	11 mg	9 mg
19+ years	11 mg	8 mg

## Tolerable Upper Intake Levels:

Age	Male	Female
0-6 months	4 mg	4 mg
7-12 months	5 mg	5 mg
1-3 years	7 mg	7 mg
4-8 years	12 mg	12 mg
9-13 years	23 mg	23 mg
14-18 years	34 mg	34 mg
19+ years	40 mg	40 mg

- N / V / D
- ↓ appetite
- Abdominal cramping
- Headaches
- ↓ copper levels
- Altered iron function
- ↓ immune function



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS

National Institutes of Health. Zinc Fact Sheet. <https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/>



# Zinc Salts

Equivalent to 1 mg  
elemental zinc ...

Zinc acetate ... 2.8 mg  
Zinc gluconate ... 7.14 mg  
Zinc sulfate ....4.4 mg

## Common Zinc Salt Products

- Zinc gluconate lozenge ... 13.3 mg elemental zinc
- Zinc sulfate 220 mg ... 50 mg elemental zinc



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS



# Zinc & Infectious Diseases

12-month placebo-controlled trial:

## Population

 49  
elderly  
patients

## Intervention



45 mg  
zinc/day  
vs.  
Placebo

## Results



Infection  
rate:  
29% vs. 88%


## Infection Types



- Cold
- URI
- Fever
- Flu



# The Common Cold




Rhinovirus  
Influenza  
Adenovirus  
Parainfluenza  
RSV  
Enterovirus  
**Coronavirus**



# Zinc & SARS-CoV

- Pyritohine (PT): zinc ionophore
  - Transports zinc intracellularly
- ↑ zinc via ↑ PT = Ø replication of SARS-CoV
  - RNA synthesis catalyzed by an RNA-dependent RNA polymerase (RdRp)
  - Ø RdRp elongation
  - ↓ template binding



↑ PT ↓ green-fluorescent protein-marked SARS-CoV.  
Blue = 0  $\mu\text{M}$ ; green = 1  $\mu\text{M}$ ; black = 2  $\mu\text{M}$  ZnOA<sub>C2</sub>



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS


te Velthuis AJW, et al. PLoS Pathogens. 2010;6:e1001176. <https://doi.org/10.1371/journal.ppat.1001176>

# Zinc & Chloroquine

OPEN  ACCESS Freely available online



## Chloroquine Is a Zinc Ionophore



- Chloroquine enhanced intracellular zinc uptake
- Zinc enhanced cytotoxic activity of chloroquine

FluoZin-3




SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS

Xue J, et al. PLoS ONE. 2014;9:e109180. <https://doi.org/10.1371/journal.pone.0109180>



# Proposed Mechanisms of Action



# Zinc & COVID-19 Outcomes



Healthy volunteer  
n=45



vs.

COVID-19 +  
n=47

<sup>30</sup>  
**Zn**  
Zinc

Median:  
105.8 mcg/dL

<sup>30</sup>  
**Zn**  
Zinc

Median:  
74.5 mcg/dL



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS


Jothimani D et al. Int J Infect Dis 2020;100:343-9. doi: 10.1016/j.ijid.2020.03.014



# Zinc & COVID-19 Outcomes



vs.



<sup>30</sup>  
**Zn**  
Zinc  
Median:  
105.8 mcg/dL

<sup>30</sup>  
**Zn**  
Zinc  
Median:  
74.5 mcg/dL



Complications	30.0%	70.4%	p=0.009
Corticosteroids	10.0%	44.5%	p=0.022
ARDS	0%	18.5%	p=0.063
Hypotension	0%	14.8%	p=0.126
Sepsis	0%	3.7%	p=1.0
ICU	10.0%	25.9%	p=0.266
Death	0%	18.5%	p=0.06
LOS >7 days	30.0%	59.3%	p=0.047


Jothimani D et al. Int J Infect Dis 2020;100:343-9. doi: 10.1016/j.ijid.2020.03.014



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS

# Zinc in SARS-CoV-2

+ COVID 19  
Hospitalized



Txt + Zinc (n=196)  
Control (n=46)



April 11, 2020

	<b>Txt + Zinc</b>	<b>Control</b>
<b>HCQ</b>	191 (97.4)	32 (69.6)
<b>Lopinavir/ritonavir</b>	114 (58.1)	13 (28.3)
<b>IL-6 inhibitor</b>	71 (36.2)	9 (19.6)
<b>Steroids</b>	56 (28.6)	6 (13.0)



# Zinc in SARS-CoV-2

↑ risk of in-hospital mortality:

- Older age
- Male sex
- ↑ severity of illness

↓ risk of in-hospital mortality:

- IL-6 inhibitor

**Mortality: Zinc: 37.2% vs. Control: 45.7% (NS)**

## **Conclusion:**

*“Our analyses demonstrate the lack of a causal association between zinc and the survival of hospitalized patients with COVID-19”*




SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS

Yao JS et al. Chest 2020 doi: <https://doi.org/10.1016/j.chest.2020.06.082>



# Zinc in SARS-CoV-2

+ COVID 19  
Hospitalized



Hydroxychloroquine + Azithromycin

n=521

HCQ + Azithro + Zinc

n=411

March 2, 2020

March 25, 2020

April 5, 2020



Hydroxychloroquine 400mg x 1 then 200 mg PO BID; Azithromycin 500 mg PO daily; Zinc sulfate 220 mg PO daily; all x 5 days



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS

Carlucci PM et al. J Med Microbiol. 2020;69:1228-34. doi: 10.1099/jmm.0.001250

# Zinc in SARS-CoV-2

## Univariate Analysis

- Hospital LOS
  - MV duration
  - O<sub>2</sub> flow rate
  - FiO<sub>2</sub>
- ∅

## Bivariate Analysis

- ↓ Mortality/hospice  
OR 0.511, 95% CI 0.359-0.726
- ↓ Need for ICU  
OR 0.545, 95% CI 0.362-0.821
- ↓ Need for invasive ventilation  
OR 0.562, 95% CI 0.354-0.891

	<u>Zinc</u>	<u>No Zinc</u>
ICU:	73.6%	74.4%
Ward:	6.9%	13.2%


# Zinc in SARS-CoV-2

## Conclusions:

- Zinc + hydroxychloroquine/azithromycin decreased mortality in a non-ICU population
- Zinc may have a role in preventing progression to severe disease
  - May not be effective once “cytokine storm” occurs
- ***“This study should not be used to guide clinical practice. Rather ... support the initiation of future randomized clinical trials...”***

# COVID A to Z: RCT


+ COVID 19  
Outpatient



↑  
Day 28

## Weekly Symptom Questionnaire

0 no symptoms      1 mild symptoms      2 moderate symptoms      3 severe symptoms



- **Fevers/chills**
- **Shortness of breath**
- **Cough**
- **Fatigue**
- Muscle/body aches
- Headache
- Loss of taste
- Loss of smell
- Congestion/runny nose
- Nausea
- Vomiting
- Diarrhea

# COVID A to Z: RCT

## Results:



Interim Analysis @ 40% = Terminated for Futility

### Primary Endpoint: Time (days) to 50% ↓ symptom severity score

<u>Vit C:</u>	<u>Zinc:</u>	<u>Both:</u>	<u>Usual:</u>
5.5 days	5.9 days	5.5 days	6.7 days

## Conclusions:

***"The addition of vit C, zinc, or both did not shorten the duration of COVID-19 symptoms"***

# Current Zinc-COVID-19 Trials

## Treatment:

**NCT04392427**

- Nitazoxanide
- Ribavirin
- Ivermectin
- Zinc

**NCT04641195**

- Zinc
- Vit D

**NCT04342728**

- Zinc
- Vit C

**NCT04558424**

- Zinc
- Vit C

**NCT04323228**

- Vit A
- Vit C
- Vit E
- Selenium
- Zinc

**NCT04621461**

- HCQ
- Azithromycin
- Zinc

**NCT04584567**

- Zinc
- Vit D

**NCT04542993**

- Zinc
- Resveratrol

**NCT04507867**

- Nutritional supplement (with zinc)

## Prophylaxis:

**NCT04551339**

- Zinc

**NCT04584567**

- Doxycycline
- Zinc

**NCT04335084**

- HCQ
- Zinc
- Vit C
- Vit D

**NCT04590274**

- HCQ
- Zinc
- Azithromycin
- Vit C
- Vit D
- NAC
- Elderberry
- Quercetin

# Zinc

# Doses & Toxicity

## Recommended Daily Intake:

Age	Male	Female
0-6 months	2 mg	2 mg
7-12 months	3 mg	3 mg
1-3 years	3 mg	3 mg
4-8 years	5 mg	5 mg
9-13 years	8 mg	8 mg
14-18 years	11 mg	9 mg
19+ years	11 mg	8 mg

## Tolerable Upper Intake Levels:

Age	Male	Female
0-6 months	4 mg	4 mg
7-12 months	5 mg	5 mg
1-3 years	7 mg	7 mg
4-8 years	12 mg	12 mg
9-13 years	23 mg	23 mg
14-18 years	34 mg	34 mg
19+ years	40 mg	40 mg

- N / V / D
- ↓ appetite
- Abdominal cramping
- Headaches
- ↓ copper levels
- Altered iron function
- ↓ immune function



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS

National Institutes of Health. Zinc Fact Sheet. <https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/>



- Zinc is a *polyvalent cation* – caution with oral co-administration
- **HIV medications:** bictegravir, dolutegravir, elvitegravir, raltegravir
- **Antibiotics:** quinolones, tetracyclines
- **Diuretics:** (chlorthalidone, hydrochlorothiazide) may ↑ urinary zinc excretion
- ↑ iron may ↓ zinc
- ↑ zinc may ↓ copper




# COVID-19 Guidelines

Guideline	Zinc	Citation
IDSA (Infectious Diseases Society of America)	No mention	<a href="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/">https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</a>
WHO (World Health Organization)	No mention	<a href="https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected">https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected</a>
SCCM (Society of Critical Care Medicine – Surviving Sepsis Campaign)	No mention	<a href="https://www.sccm.org/getattachment/Disaster/SS-C-COVID19-Critical-Care-Guidelines.pdf?lang=en-US">https://www.sccm.org/getattachment/Disaster/SS-C-COVID19-Critical-Care-Guidelines.pdf?lang=en-US</a>
NICE (National Institute for Health and Care Excellence)	No mention	<a href="https://www.nice.org.uk/covid-19">https://www.nice.org.uk/covid-19</a>
NIH (National Institutes of Health)	<ul style="list-style-type: none"><li>• Txt: insufficient data</li><li>• Ppx: remain within RDA dosing</li></ul>	<a href="https://covid19treatmentguidelines.nih.gov/introduction/">https://covid19treatmentguidelines.nih.gov/introduction/</a>



# Summary

- Zinc is a trace element
- Body of evidence in COVID-19:
  - 2 retrospective studies → *no appreciable benefit*
  - Additional studies pending
- National treatment guidelines → *do not recommend use*



# Zinc

A Review of Pertinent Drug Information for SARS-CoV-2

**Monica V. Mahoney, PharmD, BCPS AQ-ID, BCIDP**

**Clinical Pharmacy Specialist, Beth Israel Deaconess Medical Center**

[mmahoney@bidmc.harvard.edu](mailto:mmahoney@bidmc.harvard.edu)

 @mmPharmD

*Data as of Feb 20, 2021*



SOCIETY OF INFECTIOUS  
DISEASES PHARMACISTS

